BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 26336612)

  • 1. The Diagnostic and Differential Diagnosis Utility of Cerebrospinal Fluid α -Synuclein Levels in Parkinson's Disease: A Meta-Analysis.
    Zhou B; Wen M; Yu WF; Zhang CL; Jiao L
    Parkinsons Dis; 2015; 2015():567386. PubMed ID: 26336612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post mortem cerebrospinal fluid α-synuclein levels are raised in multiple system atrophy and distinguish this from the other α-synucleinopathies, Parkinson's disease and Dementia with Lewy bodies.
    Foulds PG; Yokota O; Thurston A; Davidson Y; Ahmed Z; Holton J; Thompson JC; Akiyama H; Arai T; Hasegawa M; Gerhard A; Allsop D; Mann DM
    Neurobiol Dis; 2012 Jan; 45(1):188-95. PubMed ID: 21856424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic utility of CSF α-synuclein species in Parkinson's disease: protocol for a systematic review and meta-analysis.
    Eusebi P; Giannandrea D; Biscetti L; Abraha I; Chiasserini D; Orso M; Calabresi P; Parnetti L
    BMJ Open; 2016 Jun; 6(6):e011113. PubMed ID: 27297011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.
    Chiasserini D; Biscetti L; Eusebi P; Salvadori N; Frattini G; Simoni S; De Roeck N; Tambasco N; Stoops E; Vanderstichele H; Engelborghs S; Mollenhauer B; Calabresi P; Parnetti L
    Alzheimers Res Ther; 2017 Jul; 9(1):52. PubMed ID: 28750675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson's disease diagnosis: a systematic review and meta-analysis.
    Gao L; Tang H; Nie K; Wang L; Zhao J; Gan R; Huang J; Zhu R; Feng S; Duan Z; Zhang Y; Wang L
    Int J Neurosci; 2015; 125(9):645-54. PubMed ID: 25202803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced alpha-synuclein in cerebrospinal fluid in synucleinopathies: evidence from a meta-analysis.
    Sako W; Murakami N; Izumi Y; Kaji R
    Mov Disord; 2014 Nov; 29(13):1599-605. PubMed ID: 25258345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of α-synuclein oligomers in red blood cells as a potential biomarker of Parkinson's disease.
    Wang X; Yu S; Li F; Feng T
    Neurosci Lett; 2015 Jul; 599():115-9. PubMed ID: 25998655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parkinson's and Lewy body dementia CSF biomarkers.
    Parnetti L; Paciotti S; Farotti L; Bellomo G; Sepe FN; Eusebi P
    Clin Chim Acta; 2019 Aug; 495():318-325. PubMed ID: 31051162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal fluid and plasma distribution of anti-α-synuclein IgMs and IgGs in multiple system atrophy and Parkinson's disease.
    Folke J; Rydbirk R; Løkkegaard A; Hejl AM; Winge K; Starhof C; Salvesen L; Pedersen LØ; Aznar S; Pakkenberg B; Brudek T
    Parkinsonism Relat Disord; 2021 Jun; 87():98-104. PubMed ID: 34020303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebrospinal Fluid
    Constantinides VC; Majbour NK; Paraskevas GP; Abdi I; Safieh-Garabedian B; Stefanis L; El-Agnaf OM; Kapaki E
    Brain Sci; 2021 Jan; 11(1):. PubMed ID: 33477387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuropsychiatric symptoms and α-Synuclein profile of patients with Parkinson's disease dementia, dementia with Lewy bodies and Alzheimer's disease.
    Bougea A; Stefanis L; Paraskevas GP; Emmanouilidou E; Efthymiopoulou E; Vekrelis K; Kapaki E
    J Neurol; 2018 Oct; 265(10):2295-2301. PubMed ID: 30083953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined CSF α-SYN RT-QuIC, CSF NFL and midbrain-pons planimetry in degenerative parkinsonisms: From bedside to bench, and back again.
    Compta Y; Painous C; Soto M; Pulido-Salgado M; Fernández M; Camara A; Sánchez V; Bargalló N; Caballol N; Pont-Sunyer C; Buongiorno M; Martin N; Basora M; Tio M; Giraldo DM; Pérez-Soriano A; Zaro I; Muñoz E; Martí MJ; Valldeoriola F
    Parkinsonism Relat Disord; 2022 Jun; 99():33-41. PubMed ID: 35594661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders.
    Hall S; Öhrfelt A; Constantinescu R; Andreasson U; Surova Y; Bostrom F; Nilsson C; Håkan W; Decraemer H; Någga K; Minthon L; Londos E; Vanmechelen E; Holmberg B; Zetterberg H; Blennow K; Hansson O
    Arch Neurol; 2012 Nov; 69(11):1445-52. PubMed ID: 22925882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders.
    Mollenhauer B; Parnetti L; Rektorova I; Kramberger MG; Pikkarainen M; Schulz-Schaeffer WJ; Aarsland D; Svenningsson P; Farotti L; Verbeek MM; Schlossmacher MG
    J Neurochem; 2016 Oct; 139 Suppl 1():290-317. PubMed ID: 26452984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical and pathological study on early diagnosis of Parkinson's disease and dementia with Lewy bodies].
    Orimo S
    Rinsho Shinkeigaku; 2008 Jan; 48(1):11-24. PubMed ID: 18386627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of biospecimens for α-synuclein seed amplification assays in Parkinson's disease: A systematic review and network meta-analysis.
    Zheng Y; Li S; Yang C; Yu Z; Jiang Y; Feng T
    Eur J Neurol; 2023 Dec; 30(12):3949-3967. PubMed ID: 37573472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurofilament light chain and α-synuclein RT-QuIC as differential diagnostic biomarkers in parkinsonisms and related syndromes.
    Quadalti C; Calandra-Buonaura G; Baiardi S; Mastrangelo A; Rossi M; Zenesini C; Giannini G; Candelise N; Sambati L; Polischi B; Plazzi G; Capellari S; Cortelli P; Parchi P
    NPJ Parkinsons Dis; 2021 Oct; 7(1):93. PubMed ID: 34635674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CSF biomarkers β-amyloid, tau proteins and a-synuclein in the differential diagnosis of Parkinson-plus syndromes.
    Constantinides VC; Paraskevas GP; Emmanouilidou E; Petropoulou O; Bougea A; Vekrellis K; Evdokimidis I; Stamboulis E; Kapaki E
    J Neurol Sci; 2017 Nov; 382():91-95. PubMed ID: 29111028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A meta-analysis of the diagnostic utility of biomarkers in cerebrospinal fluid in Parkinson's disease.
    Xiang C; Cong S; Tan X; Ma S; Liu Y; Wang H; Cong S
    NPJ Parkinsons Dis; 2022 Nov; 8(1):165. PubMed ID: 36446820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
    Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
    Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.